Literature DB >> 3334106

Clinical aspects of renal prostaglandins and NSAID therapy.

D C Brater1.   

Abstract

Nonsteroidal antiinflammatory drugs (NSAIDs) can have a variety of effects on renal function. Excluding allergic phenomena, these are directly related to NSAID-induced inhibition of renal synthesis of prostaglandins (PGs). For the most part, renal PGs play important physiological roles only in certain pathologic conditions. Thus, patients without these diseases (such as cardiac, hepatic, or renal compromise) manifest no or only trivial effects on renal function when NSAIDs are administered. This feature is to the advantage of the clinician because it allows prospective identification of patients who are at risk for an adverse renal effect; hence, such effects can be minimized or avoided altogether. To do so requires an understanding of the various roles of PGs in the kidney and thereby the effects that one can observe from NSAIDs. This review focuses on these various roles of renal PGs and on identification of patient groups at risk for adverse renal effects of NSAIDs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3334106     DOI: 10.1016/0049-0172(88)90040-6

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  5 in total

1.  Effects of flurbiprofen on renal function in patients with moderate renal insufficiency.

Authors:  M D Murray; P K Greene; D C Brater; A K Manatunga; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

2.  Non-steroidal Anti-inflammatory Drugs: Monitoring to help prevent serious adverse effects.

Authors:  B Cardario; A A McKinnon
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

3.  Mefenamic Acid induced nephrotoxicity: an animal model.

Authors:  Muhammad Nazrul Somchit; Faizah Sanat; Gan Eng Hui; Shahrin Iskandar Wahab; Zuraini Ahmad
Journal:  Adv Pharm Bull       Date:  2014-08-10

Review 4.  An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Participants.

Authors:  H Tannenbaum; P Davis; A S Russell; M H Atkinson; W Maksymowych; S H Huang; M Bell; G A Hawker; A Juby; S Vanner; J Sibley
Journal:  CMAJ       Date:  1996-07-01       Impact factor: 8.262

5.  Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial.

Authors:  Kara Bickham; Alan J Kivitz; Anish Mehta; Nancy Frontera; Sandhya Shah; Paul Stryszak; Zoran Popmihajlov; Paul M Peloso
Journal:  BMC Musculoskelet Disord       Date:  2016-08-08       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.